Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index >20%

被引:44
作者
Kasajima, Atsuko [1 ,2 ,3 ]
Konukiewitz, Bjoern [1 ]
Oka, Naomi [3 ,4 ]
Suzuki, Hiroyoshi [4 ]
Sakurada, Akira [5 ]
Okada, Yoshinori [5 ]
Kameya, Toru [6 ]
Ishikawa, Yuichi [7 ]
Sasano, Hironobu [3 ]
Weichert, Wilko [1 ,2 ]
Kloeppel, Guenter [1 ]
机构
[1] Tech Univ Munich, Dept Pathol, Trogerstr 18, DE-81675 Munich, Germany
[2] German Canc Consortium DKTK, Heidelberg, Germany
[3] Tohoku Univ, Dept Pathol, Grad Sch Med, Sendai, Miyagi, Japan
[4] Natl Hosp Org, Sendai Med Ctr, Sendai, Miyagi, Japan
[5] Tohoku Univ, Grad Sch Med, Dept Thorac Surg, Inst Dev Aging & Canc, Sendai, Miyagi, Japan
[6] Shizuoka Canc Ctr Hosp & Res Inst, Div Pathol, Shizuoka, Japan
[7] Canc Inst Hosp JFCR, Dept Pathol, Tokyo, Japan
关键词
Lung; Neuroendocrine neoplasms; Carcinoids; WHO classification; Ki67; SMALL-CELL CARCINOMA; NEUROENDOCRINE TUMORS; HIGH-GRADE; NEOPLASMS; EXPRESSION; RB1; HETEROGENEITY; SPECIMENS; CANCER;
D O I
10.1159/000495806
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The clinicopathological features of lung neuroendocrine neoplasms (NEN) with a high proliferative index at the border area between atypical carcinoid and neuroendocrine carcinoma have not been investigated so far. The aim of this study was, therefore, to search for lung NENs which are well differentiated but show Ki67 values that overlap with those of poorly differentiated (PD)-NENs. Resected lung NENs from 244 Japanese patients were reviewed, and Ki67 indices were assessed in all tumors. The data were then correlated to clinicopathological parameters and patient outcome. Among 59 (24%) well-differentiated (WD)-NENs and 185 (76%) lung PD-NENs, 7 were defined as WD-NENs with Ki67 indices > 20%. The Ki67 indices of these tumors (mean 29%, range 24-36) were significantly lower than those of PD-NENs (mean 74%, range 34-99). All WD-NENs with Ki67 > 20% lacked abnormal p53 and loss of retinoblastoma 1 (Rb1) expression. In contrast, many PD-NENs expressed p53 (48%) and showed loss of Rb1 (86%). The 2- and 5-year disease-free survival rates in WD-NEN patients with Ki67 > 20% were lower than those of WD-NEN patients with Ki67 = 20% (p < 0.01 for disease-free and overall survival). No statistical differences were detected between outcome of WD-NEN patients with Ki67 > 20% and those of PD-NEN. It is concluded that WD-NEN patients with Ki67 > 20% share the morphological and immunohistochemical features of WD-NEN patients with Ki67 = 20%, but they have a worse prognosis, suggesting that this tumor group requires particular attention in future classifications and probably new therapeutic regimes. (c) 2018 S. Karger AG, Basel
引用
收藏
页码:109 / 120
页数:12
相关论文
共 35 条
[1]  
[Anonymous], 2017, WHO Classification of Tumours of Endocrine Organs
[2]   Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact [J].
Aslan, DL ;
Gulbahce, HE ;
Pambuccian, SE ;
Manivel, JC ;
Jessurun, J .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (06) :874-878
[3]   The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms [J].
Basturk, Olca ;
Yang, Zhaohai ;
Tang, Laura H. ;
Hruban, Ralph H. ;
Adsay, Volkan ;
McCall, Chad M. ;
Krasinskas, Alyssa M. ;
Jang, Kee-Taek ;
Frankel, Wendy L. ;
Balci, Serdar ;
Sigel, Carlie ;
Klimstra, David S. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (05) :683-690
[4]  
Bierley JD., 2017, TNM classification of malignant tumors, V8th, DOI DOI 10.1002/EJOC.201200111
[5]   Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids [J].
Caplin, M. E. ;
Baudin, E. ;
Ferolla, P. ;
Filosso, P. ;
Garcia-Yuste, M. ;
Lim, E. ;
Oberg, K. ;
Pelosi, G. ;
Perren, A. ;
Rossi, R. E. ;
Travis, W. D. .
ANNALS OF ONCOLOGY, 2015, 26 (08) :1604-1620
[6]   TYPICAL AND ATYPICAL BRONCHOPULMONARY CARCINOID-TUMORS - A CLINICOPATHOLOGICAL AND KI-67-LABELING STUDY [J].
COSTES, V ;
MARTYANE, C ;
PICOT, MC ;
SERRE, I ;
PUJOL, JL ;
MARY, H ;
BALDET, P .
HUMAN PATHOLOGY, 1995, 26 (07) :740-745
[7]   Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed -catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift [J].
Fabbri, Alessandra ;
Cossa, Mara ;
Sonzogni, Angelica ;
Bidoli, Paolo ;
Canova, Stefania ;
Cortinovis, Diego ;
Abbate, Maria Ida ;
Calabrese, Fiorella ;
Nannini, Nazarena ;
Lunardi, Francesca ;
Rossi, Giulio ;
La Rosa, Stefano ;
Capella, Carlo ;
Tamborini, Elena ;
Perrone, Federica ;
Busico, Adele ;
Capone, Iolanda ;
Valeri, Barbara ;
Pastorino, Ugo ;
Albini, Adriana ;
Pelosi, Giuseppe .
VIRCHOWS ARCHIV, 2017, 471 (01) :31-47
[8]   Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications [J].
Fazio, Nicola ;
Milione, Massimo .
CANCER TREATMENT REVIEWS, 2016, 50 :61-67
[9]   Prognostic markers in patients with typical bronchial carcinoid tumors [J].
Granberg, D ;
Wilander, E ;
Öberg, K ;
Skogseid, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (09) :3425-3430
[10]  
Grimaldi F, 2011, FRONT ENDOCRINOL, V19, P2